- Home
- BATL vs GDTC Comparison
BATL vs GDTC Comparison
Compare BATL & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- GDTC
- Stock Information
- Founded
- BATL 1987
- GDTC 2018
- Country
- BATL United States
- GDTC Singapore
- Employees
- BATL N/A
- GDTC N/A
- Industry
- BATL Oil & Gas Production
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- BATL Energy
- GDTC Health Care
- Exchange
- BATL Nasdaq
- GDTC Nasdaq
- Market Cap
- BATL 19.3M
- GDTC 22.9M
- IPO Year
- BATL N/A
- GDTC 2023
- Fundamental
- Price
- BATL $1.07
- GDTC $1.93
- Analyst Decision
- BATL
- GDTC Buy
- Analyst Count
- BATL 0
- GDTC 1
- Target Price
- BATL N/A
- GDTC $5.00
- AVG Volume (30 Days)
- BATL 387.2K
- GDTC 10.1K
- Earning Date
- BATL 08-14-2025
- GDTC 01-01-0001
- Dividend Yield
- BATL N/A
- GDTC N/A
- EPS Growth
- BATL N/A
- GDTC N/A
- EPS
- BATL N/A
- GDTC N/A
- Revenue
- BATL $185,206,000.00
- GDTC $368,838.00
- Revenue This Year
- BATL N/A
- GDTC $5.37
- Revenue Next Year
- BATL N/A
- GDTC N/A
- P/E Ratio
- BATL N/A
- GDTC N/A
- Revenue Growth
- BATL N/A
- GDTC N/A
- 52 Week Low
- BATL $1.02
- GDTC $1.20
- 52 Week High
- BATL $6.89
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- BATL 35.35
- GDTC 51.21
- Support Level
- BATL $1.02
- GDTC $1.85
- Resistance Level
- BATL $1.21
- GDTC $2.07
- Average True Range (ATR)
- BATL 0.09
- GDTC 0.08
- MACD
- BATL 0.00
- GDTC 0.02
- Stochastic Oscillator
- BATL 18.52
- GDTC 57.26
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.